SCHEMBL2403987

SCHEMBL2403987

CCc1ccc(-c2nnc(SCC(=O)Nc3nc4ccc(F)cc4s3)[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WNT3A P56704 3/20 0.52
▸ PTPN1 P18031 1/20 0.48
▸ TP53 P04637 3/20 0.48
▸ PDPK1 O15530 1/20 0.47
▸ DYRK1A Q13627 1/20 0.47
▸ MAPT P10636 7/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 1/20 0.47
▸ POLB P06746 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ AKT1 P31749 1/20 0.45
▸ CSNK1D P48730 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ PTPRC P08575 1/20 0.44
▸ PTPN7 P35236 1/20 0.44
▸ PTPN12 Q05209 1/20 0.44
▸ PTPN22 Q9Y2R2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406227 0.87 MAPT (0.58) TP53MAPTALDH1A1LMNAMEN1
SCHEMBL2403580 0.81 POLB (0.51) TP53MAPTALDH1A1POLBMEN1
SCHEMBL2402371 0.81 MAPT (0.54) TP53MAPTALDH1A1POLBMEN1
SCHEMBL2403291 0.80 ALDH1A1 (0.49) TP53MAPTALDH1A1POLBLMNA
SCHEMBL2403847 0.79 ESR2 (0.50) TP53MAPTALDH1A1POLBLMNA
SCHEMBL2403626 0.77 HTT (0.53) TP53MAPTALDH1A1HPGDPOLB
SCHEMBL2527359 0.76 MAPT (0.62) TP53MAPTALDH1A1HPGDPOLB
SCHEMBL2405771 0.76 KMT2A (0.53) TP53MAPTALDH1A1LMNAMEN1
SCHEMBL2410919 0.75 CYP1A2 (0.52) TP53MAPTALDH1A1POLBLMNA
SCHEMBL2402164 0.75 RAB9A (0.51) TP53MAPTALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9381172-B2 Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2016-07-05 — — US disclosed
US-9381172-B2 Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2016-07-05 — — US disclosed
US-9381172-B2 Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2016-07-05 — — US disclosed
US-20130012557-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2013-01-10 — — US disclosed
US-20130012557-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2013-01-10 — — US disclosed
US-20130012557-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2013-01-10 — — US disclosed
US-20110212994-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders CLEM BRIAN 2011-09-01 — — US disclosed
US-20110212994-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders CLEM BRIAN 2011-09-01 — — US disclosed
US-20110212994-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders CLEM BRIAN 2011-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212994-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders CHKB, CHKA, CHAT WNT3A 2512/4885PTPN1 3897/4885TP53 743/4885
US-20130012557-A1 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders CHKB, CHKA, CHAT WNT3A 2724/4885PTPN1 4014/4885TP53 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback